In May 2021, ETAP-Lab is adding its latest mouse model of Alzheimer's disease to its catalogue. Using our expertise in the manufacture of oligomers from A-beta1-42 peptide, we have demonstrated that these compounds are toxic to the central nervous systems of aged mice and cause changes in the expression of synaptic markers and apoptotic signalling, associated with a decrease in their memory capacity. ETAP-Lab has been producing A-beta1-42 peptide oligomers since 2019, and offers an in vitro testing service for the screening
ETAP-Lab will be attending BIODigital as part of the BusinessFrance virtual French pavilion (from 10 to 18 June). Our experts Dr. Jean-François Bisson (VP) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory's activities in preclinical Dermatology, NutritionHealth and Neurology, with Stroke, Alzheimer’s and Parkinson’s diseases. Please feel free to contact us to schedule a video conference. We’re hoping to meet you soon!